Trial results focusing on improving screening and therapy for Hispanic/Latinx patients at risk for Chronic Kidney Disease (CKD) and Type 2 Diabetes were posted on 2026-04-24. The study enrolled 248 participants to assess the uptake of screening and specific treatments.
Background
Type 2 Diabetes and Chronic Kidney Disease are significant health concerns, particularly within Hispanic/Latinx and Black communities. Early screening for kidney disease, such as the urine albumin-to-creatinine ratio (uACR), and appropriate therapeutic interventions are crucial for slowing disease progression. Recommended treatments often include SGLT2 inhibitors (SGLT2i), GLP-1 receptor agonists (GLP-1 RA), and renin-angiotensin-aldosterone system inhibitors (RAASi). This study aimed to address disparities in care by implementing strategies to improve screening and treatment for these at-risk populations.
Trial design
This completed study enrolled 248 participants, focusing on conditions including Type 2 Diabetes and Chronic Kidney Diseases. The trial's objectives included utilizing community organizations to screen Hispanic/Latino(a)s for kidney disease, diabetes, and other risk factors, and referring them for primary care. Additionally, an intervention was implemented in local health clinics to assist primary care physicians (PCPs) with screening and treating Hispanic and Black patients with diabetes. The study involved two main approaches for data collection: a "Screening/Treatment Group" and an "Optimal Care Group" for certain outcome measurements.
Key results
The study reported several key measurements related to screening and treatment uptake:
- Number of Participants Who Attended or Scheduled a Primary Care Physician (PCP) Visit:
- For Hispanic/Latinx Patients at Risk for Chronic Kidney Disease (CKD), 14 participants attended or scheduled a PCP visit.
- Number of Participants Who Received Urine Albumin-to-Creatinine Ratio (uACR) Screening:
- In the Screening/Treatment Group, 40 participants received uACR screening.
- In the Optimal Care Group, 92 participants received uACR screening.
- Number of Participants Who Were Prescribed an SGLT2 Inhibitor (SGLT2i) and/or a GLP-1 Receptor Agonist (GLP-1 RA):
- In the Screening/Treatment Group, 16 participants were prescribed an SGLT2i and/or a GLP-1 RA.
- In the Optimal Care Group, 68 participants were prescribed an SGLT2i and/or a GLP-1 RA.
- Number of Participants Who Were Prescribed a Renin-Angiotensin-Aldosterone System Inhibitor (RAASi):
- In the Screening/Treatment Group, 2 participants were prescribed a RAASi.
- In the Optimal Care Group, 74 participants were prescribed a RAASi.
What this means
The results provide specific counts regarding the implementation of screening and treatment strategies for Type 2 Diabetes and Chronic Kidney Disease within targeted populations. The data indicates the number of participants who engaged with primary care, received uACR screening, and were prescribed guideline-recommended medications such as SGLT2 inhibitors, GLP-1 receptor agonists, and RAAS inhibitors. For instance, the Optimal Care Group showed higher numbers for uACR screening (92 participants), SGLT2i/GLP-1 RA prescriptions (68 participants), and RAASi prescriptions (74 participants) compared to the Screening/Treatment Group. These findings offer insights into the reach and effectiveness of the implemented interventions aimed at improving care for Hispanic/Latinx and Black patients at risk for kidney disease progression.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study titled "Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD" were posted on 2026-04-24 on clinicaltrials.gov.